Extracorporeal management of severe methotrexate toxicity and acute kidney injury in the absence of glucarpidase Authors: Taylor Purzycki, Matthew Knapp, Shivangi Patel Published: 2025 ABSTRACT SummaryMethotrexate (MTX) is widely used in oncology but carries a risk of severe nephrotoxicity, especially at high doses. We report a case of a man in his 70s with diffuse large B-cell lymphoma who developed acute kidney injury (AKI) and refractory hypotension 48 hours after receiving high-dose methotrexate (HD-MTX). Despite standard interventions including leucovorin rescue and urine alkalinisation, MTX clearance was impaired due to AKI. In the absence of glucarpidase, the patient was successfully managed with intermittent high-flux haemodialysis followed by continuous renal replacement therapy. This approach facilitated gradual MTX clearance, resolution of hypotension and recovery of renal function. This case highlights the critical need for early recognition of MTX toxicity and the potential role of individualised extracorporeal therapies when glucarpidase is unavailable. Background Methotrexate (MTX), a folate antagonist, is a cornerstone in treating haematologic malignancies, including diffuse large B-cell lymphoma.1 Despite its efficacy, MTX carries a significant risk of toxicity. Severe toxicities, which can be fatal, include hepatotoxicity, pneumonitis, neurotoxicity and nephrotoxicity.2 Nephrotoxicity occurs from direct tubular injury and crystal precipitation in renal tubules.3 Standard first-line therapies to mitigate toxicity involve leucovorin rescue and urine alkalinisation, which enhance MTX elimination and protect normal cells.2 Glucarpidase, an enzyme that rapidly degrades circulating MTX, is the preferred treatment for severe toxicity.2 However, glucarpidase is not always available, necessitating alternative approaches such as high-flux haemodialysis or continuous renal replacement therapy (CRRT) to remove MTX extracorporeally.4 Case presentation A man in his 70s with a history of diffuse large B-cell lymphoma in remission presented with fever, cough and shortness of breath. Imaging revealed multifocal pneumonia, treated with antibiotics and non-invasive ventilation. During hospitalisation, he developed bilateral eye ptosis and progressively worsening bilateral upper and lower extremity weakness. Recurrence of lymphoma was confirmed by lumbar puncture and MRI, which revealed an epidural mass at S1–S2. A bicarbonate infusion was initiated to alkalinise the urine. Once a target urine pH of >8.0 was achieved, the patient received high-dose methotrexate (HD-MTX), with a dose of 3500 mg/m2. Per protocol, intravenous leucovorin (50 mg every 6 hours) was administered 24 hours after receiving HD-MTX. Forty-eight hours post infusion, the patient became acutely hypotensive (BP 74/45 mm Hg). Despite fluid resuscitation, he required vasopressor support with norepinephrine. Serum creatinine rose from 0.53 mg/dL to 1.50 mg/dL, despite preserved urine output. Investigations and differential diagnosis A comprehensive diagnostic workup was performed to identify the cause of hypotension. Septic shock was initially considered due to the patient’s recent multifocal pneumonia and immunocompromised state. However, it was excluded based on a normal white blood cell count, lactate, procalcitonin levels and negative culture results. CT of the chest, abdomen and pelvis did not demonstrate evidence of infection. Furthermore, CT imaging did not show evidence of hydronephrosis, obstruction or structural abnormalities to explain the rise in creatinine. Cardiac causes were ruled out based on normal ECG and echocardiogram findings. Hypovolaemia was excluded, as the patient did not respond to fluid resuscitation and ultimately required vasopressors. There was no evidence of active bleeding, with haemoglobin stable at 105 g/L compared with 100 g/L the day prior. The patient’s oxygen requirements were unchanged from admission, and pulmonary embolism was considered unlikely given ongoing anticoagulation for atrial fibrillation. Adrenal insufficiency was considered unlikely given the patient’s ongoing treatment with dexamethasone for eye ptosis. Furthermore, labs did not demonstrate hyperkalaemia, hyponatraemia or hypoglycaemia. A head CT showed parenchymal volume loss and non-specific white matter changes, not consistent with acute neurologic causes. The spinal lesion at the S1–S2 level was anatomically incompatible with neurogenic shock, which typically results from injuries above the T6 level that disrupt the sympathetic nervous system. After all other aetiologies of hypotension were ruled out, the hypotension and acute kidney injury (AKI) were thought to be secondary to MTX toxicity. A MTX level was obtained and noted to be ~86 µmol/L (normal <10, severe toxicity >10). Treatment To enhance renal clearance of MTX, intravenous fluid was adjusted by increasing the sodium bicarbonate concentration from 100 mEq/L to 150 mEq/L and raising the infusion rate from 125 mL/hour to 150 mL/hour. Leucovorin was initially continued at 50 mg every 6 hours. Due to worsening AKI, indicated by a serum creatinine three times his baseline, and rising MTX levels despite standard first-line treatment, intermittent haemodialysis was initiated, as glucarpidase was not available. Haemodialysis was carried out using a high-flux membrane and standard dialysate (4K, 2.5Ca), without fluid removal, as the patient was euvolemic at the time. A repeat MTX level measured 4 hours after dialysis showed a concentration of ~45 µmol/L. The patient’s hypotension resolved, and vasopressors were discontinued. However, he developed fluid overload, evidenced by lower extremity oedema and a net positive fluid balance of 3.3 L, despite 1.6 L of urine output. This was attributed to a combination of AKI and ongoing intravenous fluids required for urine alkalinisation. To manage fluid balance, prevent MTX rebound and continue drug clearance, CRRT, specifically haemodiafiltration, using a high-flux membrane was initiated. To address both leucovorin removal during CRRT and the severity of MTX toxicity, the leucovorin dose was increased from 50 mg every 6 hours to 150 mg every 6 hours. Electrolytes were monitored every 12 hours, and MTX levels were checked daily to guide therapy. Outcome and follow-up After 5 days of CRRT, the MTX level decreased to 1.46 µmol/L, and CRRT was discontinued (see figure 1). Kidney function normalised, and the patient was discharged to oncology for further management. Creatinine versus MTX levels over the hospital course. Serum methotrexate (MTX) (µmol/L) and creatinine (mg/dL) levels are shown by hospital day. Haemodialysis (HD) was initiated on day 2, transitioned to continuous renal replacement therapy (CRRT) on day 3 and discontinued on day 7. The patient was subsequently discharged with recovery of renal function. Discussion MTX is a folate analogue that blocks dihydrofolate reductase (DHFR), an enzyme needed to make active folate. This disruption impairs DNA, RNA and protein synthesis, especially in rapidly dividing cells.1 Because of this, MTX is effective in treating rheumatological and oncological conditions.1 Despite its therapeutic benefits, MTX carries a risk of significant toxicity, particularly at high doses. A serum MTX level greater than 10 µmol/L is indicative of severe toxicity,5 and doses ≥500 mg/m2 or greater are classified as HD-MTX.2 At 48 hours post infusion, the patient’s MTX level was ~86 µmol/L—well above expected levels (<5, <0.1 and <0.05 µmol/L at 24, 48 and 72 hours, respectively).6 During this period, he developed profound hypotension that was refractory to intravenous fluids and required vasopressor support. MTX has been reported to lower blood pressure even at low doses.7 For example, one study demonstrated a mean 7.4 mm Hg reduction in systolic blood pressure after 6 months of therapy compared with another rheumatoid arthritis agent.8 MTX indirectly inhibits adenosine deaminase, leading to accumulation of adenosine, a potent vasodilator.9 Low-dose MTX can induce adenosine elevation leading to a modest decrease in blood pressure. Therefore, higher doses of MTX can plausibly result in more pronounced vasodilator effects of adenosine leading to profound hypotension. In addition to causing vasodilation in most vascular beds, adenosine can also reduce sympathetic tone, which further contributes to lowering blood pressure.10 Supporting a haemodynamic impact at higher doses, a retrospective study of ICU patients receiving HD-MTX found that 30% required vasopressors, although the exact mechanism was not clarified.11 In our patient, other causes of hypotension were excluded, and temporal association with MTX administration suggested drug toxicity as the primary cause. Notably, vasopressor requirements resolved following dialysis, coinciding with a ~50% reduction in MTX levels, further supporting this relationship. Further research is needed to elucidate the mechanisms underlying MTX-induced hypotension, particularly the role of adenosine in mediating these effects. The patient also developed AKI, with creatinine rising to 1.5 mg/dL from a baseline of 0.53 mg/dL 24 hours earlier. AKI occurs in 2–12% of HD-MTX recipients,12 typically presenting as non-oliguric renal failure.13 Therefore, urine output cannot be used to gauge severity of renal failure or recovery of renal function in MTX toxicity. MTX can cause renal injury through various mechanisms. It directly damages proximal tubular cells, impairing solute and water reabsorption. MTX also induces renal vasoconstriction via adenosine, reducing renal blood flow and glomerular filtration. In addition, MTX’s poor solubility can lead to crystal precipitation in the tubules, causing obstruction, local inflammation and interstitial nephritis.3 9 Since 80–90% of MTX is renally cleared, delayed elimination can increase MTX levels, further worsening AKI and initiating a vicious cycle.14 AKI associated with HD-MTX usually develops within 48–72 hours and precedes toxicity in other organs such as the gastrointestinal tract, nervous system, liver, lungs, skin and bone marrow.15 To mitigate toxicity, leucovorin (folinic acid) is administered. Leucovorin bypasses DHFR inhibition, thereby restoring DNA, RNA and protein synthesis in normal cells.12 However, its efficacy diminishes as MTX levels rise, necessitating dose adjustments based on MTX concentrations. While leucovorin is most effective when administered within 24 hours of MTX, delayed administration reduces its protective effect.12 Simultaneously, intravenous bicarbonate and oral bicarbonate are given to maintain urine output and alkalinise the urine, preventing MTX-AKI.2 Urine alkalinisation enhances MTX solubility, reducing intratubular precipitation and the risk of crystal-induced nephropathy.12 Given the patient’s MTX level exceeded 10 µmol/L and creatinine rose to three times baseline, glucarpidase was indicated to rapidly eliminate extracellular MTX by converting it into inactive metabolites.2 3 12 Although glucarpidase effectively lowers systemic MTX levels, its efficacy in established AKI remains uncertain, as it acts only on extracellular MTX and does not address intratubular crystal deposition, renal inflammation or intracellular drug accumulation.15 Nevertheless, by decreasing circulating MTX levels, glucarpidase may help limit further renal injury.15 Although glucarpidase has demonstrated effectiveness even beyond 60 hours post-MTX administration, it was not readily available at our institution.16 The 2022 Extracorporeal Treatments in Poisoning Workgroup recommendations generally advise against the use of extracorporeal treatments such as haemodialysis or CRRT for MTX toxicity, citing limited evidence of clinical benefit and risks associated with these modalities. However, these guidelines acknowledge that extracorporeal therapy may be considered in select cases of severe toxicity or when glucarpidase is unavailable.17 In this case, glucarpidase was not available, prompting initiation of intermittent haemodialysis using a high-flux membrane to reduce prolonged MTX exposure and mitigate AKI. Similar to glucarpidase, high-flux HD facilitates removal of extracellular MTX. After a 4-hour dialysis session, MTX levels declined to 45 µmol/L, and vasopressor support was discontinued—suggesting that elevated MTX levels were the cause of hypotension. Despite this, creatinine remained elevated at 1.3 mg/dL, indicating ongoing AKI. Successful MTX elimination with intermittent haemodialysis has been reported in the literature.18 One case series involving patients with AKI following HD-MTX demonstrated effective MTX clearance using daily high-flux dialysis sessions lasting 6 hours. However, this study showed that MTX levels rebounded by a median of 40% after each dialysis session.18 Due to the ongoing need for intravenous fluids to alkalinise the urine and persistent AKI limiting free water clearance, the patient became fluid overloaded. Therefore, CRRT, specifically haemodiafiltration with a high-flux membrane, was initiated. This approach allowed for gradual fluid removal, improved haemodynamic stability and steady MTX clearance while minimising rebound. After initiating CRRT, MTX rapidly declined to a level less than 10 (non-toxic level). However, we observed a single rebound of MTX to 6.8 after an initial decline to 1.19, despite ongoing CRRT and stable haemodynamics. We infer that rebound MTX levels can be used as another objective data point to help determine the appropriate timing for discontinuing CRRT, in conjunction with MTX levels, haemodynamic stability and volume status. Similar to the findings of Connors et al, this case highlights the use of CRRT to reduce MTX levels and underscores its potential role in managing MTX toxicity in the setting of concurrent renal impairment and fluid overload.19 Both intermittent HD and CRRT are resource-intensive and require prolonged vascular access, introducing risks such as infection and thrombosis.20 However, the availability of high-flux membranes for both modalities at our institution allowed us to tailor extracorporeal therapy to the patient’s evolving clinical needs. Aggressive elimination of MTX was implemented to avoid fatal complications of other end organ toxicity. Leucovorin was continued to minimise the intracellular effects of MTX, while CRRT was used to enhance extracellular clearance of MTX from the bloodstream. This approach was necessary to manage MTX toxicity comprehensively, targeting both cellular rescue and systemic drug clearance, particularly in the absence of glucarpidase. Learning points Early recognition and monitoring of methotrexate (MTX) levels and renal function are essential to prevent and mitigate MTX toxicity. Early recognition and monitoring of methotrexate (MTX) levels and renal function are essential to prevent and mitigate MTX toxicity. First-line treatments include leucovorin rescue and urine alkalinisation, which reduce MTX nephrotoxicity and enhance drug elimination, primarily from the intracellular compartment. First-line treatments include leucovorin rescue and urine alkalinisation, which reduce MTX nephrotoxicity and enhance drug elimination, primarily from the intracellular compartment. High-flux dialysis (intermittent or continuous) is an important alternative or adjunct to reduce MTX levels from the extracellular compartment, when glucarpidase is unavailable or in cases of acute kidney injury (AKI). High-flux dialysis (intermittent or continuous) is an important alternative or adjunct to reduce MTX levels from the extracellular compartment, when glucarpidase is unavailable or in cases of acute kidney injury (AKI). Continuous renal replacement therapy (CRRT) is preferred for patients with fluid overload and/or haemodynamic instability because it allows gradual fluid removal while maintaining stable haemodynamics. Haemodialysis (HD) is equally effective in haemodynamic stable patients but carries a risk of post-dialysis MTX rebound. Continuous renal replacement therapy (CRRT) is preferred for patients with fluid overload and/or haemodynamic instability because it allows gradual fluid removal while maintaining stable haemodynamics. Haemodialysis (HD) is equally effective in haemodynamic stable patients but carries a risk of post-dialysis MTX rebound. MTX may lead to hypotension possibly through increases in adenosine levels; however, further studies are required. MTX may lead to hypotension possibly through increases in adenosine levels; however, further studies are required.